Article

Vitreoretinal Technologies closes deal with De Novo Ventures

Irvine, CA-Vitreoretinal Technologies closed on an $8.8 million Series A financing with Investor De Novo Ventures and a group of private investors.

Irvine, CA-Vitreoretinal Technologies closed on an $8.8 million Series A financing with Investor De Novo Ventures and a group of private investors.

Vitreoretinal Technologies, a specialty pharmaceutical company, has drugs in its pipeline that are focused on diabetic retinopathy, glaucoma, and retinitis pigmentosa.

"All of us at De Novo Ventures are delighted to have the opportunity to invest in Vitreoretinal Technologies," said new board member Fred Dotzler. "The market potential for the three products, which will soon be administered to patients in phase III trials, is enormous. The positive results from previous trials are suggestive of significant clinical benefit in diabetic retinopathy, retinitis pigmentosa, and glaucoma."

"I look forward to an effective treatment option for diabetic retinopathy patients," said Vicken Karageozian, MD, co-founder and chief medical officer. "With rapidly growing rates of diabetes worldwide, Vitreosolve has the potential to be one of the most important drugs in ophthalmology."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
© 2025 MJH Life Sciences

All rights reserved.